ReviewMolecular and cellular biochemistry2025
Dysregulated homocysteine metabolism and cardiovascular disease and clinical treatments.
Review in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Effects of folic acid combined with resistance training on body composition and blood biomarkers in adult males.Journal of the International Society of Sports Nutrition · 2026Trial
- Metabolomic Atlas of Cardiovascular Diseases: Mapping Shared and Specific Signatures.JACC. Advances · 2026Article
- Modulating One-Carbon Metabolism with B-Vitamins to Protect the Retinal Barrier and Prevent Retinal Degeneration.Nutrients · 2026Article
- Triglyceride-glucose index and hyperhomocysteinemia within a cardiovascular-kidney-metabolic biomarker network: insights from interpretable machine learning and epidemiological modeling.Frontiers in nutrition · 2026Article
- Effects and Mechanisms ofInternational journal of food science · 2026Article
- Cardiac Function Transition in Patients with Chronic Kidney Disease Undergoing Maintenance Hemodialysis in a High-Altitude Multi-Ethnic Region: A Comparative Study Between Yi and Non-Yi Ethnic Groups.Journal of inflammation research · 2026Article
- Temporal trend of serum vitamin profiles and the association with non-alcoholic fatty liver disease.Frontiers in nutrition · 2026Article
- Review
- High-Sensitivity Troponins and Homocysteine: Combined Biomarkers for Better Prediction of Cardiovascular Events.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated homocysteine (Hcy) levels, known as hyperhomocysteinemia (HHcy), are recognized as a separate risk factor for cardiovascular disease. Mutations in methylenetetrahydrofolate reductase (MTHFR) and cystathionine beta synthase (CBS)-enzymes pivotal at the juncture of the trans-sulfuration and remethylation pathways-underlie the pathogenesis of HHcy. Although vitamin supplementation has been proven to effectively decrease Hcy levels, there is still uncertainty about whether this reduction translates to a decrease in the incidence rates from cardiovascular diseases (CVDs). This review seeks to explore the linking between Hcy and specific diseases, the role of Hcy in vascular homeostasis, and the research on the possible advantages of therapies designed to lower Hcy levels. Understanding the intricate mechanisms of their metabolism and interactions is essential for pharmacological treatments to mitigate the adverse effects associated with metabolic dysregulation of Hcy. Given the widespread availability and ease of use of Hcy test kits, we strongly advocate for the routine administration of rapid blood tests for individuals at high risk of CVDs, particularly among the elderly population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.